Tags

Type your tag names separated by a space and hit enter

CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases.
Am J Clin Pathol. 2008 Apr; 129(4):526-9.AJ

Abstract

The therapeutic imperative for Alzheimer disease (AD) and Parkinson disease (PD) calls for discovery and validation of biomarkers. Increased cerebrospinal fluid (CSF) tau and decreased amyloid (A) beta42 have been validated as biomarkers of AD. In contrast, there is no validated CSF biomarker for PD. We validated our proteomics-discovered multianalyte profile (MAP) in CSF from 95 control subjects, 48 patients with probable AD, and 40 patients with probable PD. An optimal 8-member MAP agreed with expert diagnosis for 90 control subjects (95%), 36 patients with probable AD (75%), and 38 patients with probable PD (95%). This MAP consisted of the following (in decreasing order of contribution): tau, brain-derived neurotrophic factor, interleukin 8, Abeta42, beta2-microglobulin, vitamin D binding protein, apolipoprotein (apo) AII, and apoE. This first large-scale validation of a proteomic-discovered MAP suggests a panel of 8 CSF proteins that are highly effective at identifying PD and moderately effective at identifying AD.

Authors+Show Affiliations

Department of Pathology, University of Washington School of Medicine, Seattle, WA 98104, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Validation Study

Language

eng

PubMed ID

18343778

Citation

Zhang, Jing, et al. "CSF Multianalyte Profile Distinguishes Alzheimer and Parkinson Diseases." American Journal of Clinical Pathology, vol. 129, no. 4, 2008, pp. 526-9.
Zhang J, Sokal I, Peskind ER, et al. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol. 2008;129(4):526-9.
Zhang, J., Sokal, I., Peskind, E. R., Quinn, J. F., Jankovic, J., Kenney, C., Chung, K. A., Millard, S. P., Nutt, J. G., & Montine, T. J. (2008). CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. American Journal of Clinical Pathology, 129(4), 526-9. https://doi.org/10.1309/W01Y0B808EMEH12L
Zhang J, et al. CSF Multianalyte Profile Distinguishes Alzheimer and Parkinson Diseases. Am J Clin Pathol. 2008;129(4):526-9. PubMed PMID: 18343778.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. AU - Zhang,Jing, AU - Sokal,Izabela, AU - Peskind,Elaine R, AU - Quinn,Joseph F, AU - Jankovic,Joseph, AU - Kenney,Christopher, AU - Chung,Kathryn A, AU - Millard,Steven P, AU - Nutt,John G, AU - Montine,Thomas J, PY - 2008/3/18/pubmed PY - 2008/5/7/medline PY - 2008/3/18/entrez SP - 526 EP - 9 JF - American journal of clinical pathology JO - Am J Clin Pathol VL - 129 IS - 4 N2 - The therapeutic imperative for Alzheimer disease (AD) and Parkinson disease (PD) calls for discovery and validation of biomarkers. Increased cerebrospinal fluid (CSF) tau and decreased amyloid (A) beta42 have been validated as biomarkers of AD. In contrast, there is no validated CSF biomarker for PD. We validated our proteomics-discovered multianalyte profile (MAP) in CSF from 95 control subjects, 48 patients with probable AD, and 40 patients with probable PD. An optimal 8-member MAP agreed with expert diagnosis for 90 control subjects (95%), 36 patients with probable AD (75%), and 38 patients with probable PD (95%). This MAP consisted of the following (in decreasing order of contribution): tau, brain-derived neurotrophic factor, interleukin 8, Abeta42, beta2-microglobulin, vitamin D binding protein, apolipoprotein (apo) AII, and apoE. This first large-scale validation of a proteomic-discovered MAP suggests a panel of 8 CSF proteins that are highly effective at identifying PD and moderately effective at identifying AD. SN - 0002-9173 UR - https://www.unboundmedicine.com/medline/citation/18343778/CSF_multianalyte_profile_distinguishes_Alzheimer_and_Parkinson_diseases_ L2 - https://academic.oup.com/ajcp/article-lookup/doi/10.1309/W01Y0B808EMEH12L DB - PRIME DP - Unbound Medicine ER -